|2.09 0.1 (5.03%)||12-07 16:00|
|Targets||6-month :||2.46||1-year :||2.87|
|Resists||First :||2.1||Second :||2.46|
|Supports||First :||1.84||Second :||1.67|
|MAs||MA(5) :||1.97||MA(20) :||1.92|
|MA(100) :||2.25||MA(250) :||2.58|
|MACD||MACD :||0||Signal :||0|
|%K %D||K(14,3) :||69||D(3) :||59.7|
|52-week||High :||3.83||Low :||1.67|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ GERN ] has closed above the upper band by 12.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 47.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||2.11 - 2.12||2.12 - 2.13|
|Low:||1.94 - 1.95||1.95 - 1.96|
|Close:||2.07 - 2.09||2.09 - 2.1|
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||0 (M)|
|Shares Float||543 (M)|
|Held by Insiders||4.9613e+008 (%)|
|Held by Institutions||0.1 (%)|
|Shares Short||44,940 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||-29 %|
|Return on Assets (ttm)||31.7 %|
|Return on Equity (ttm)||-36.6 %|
|Qtrly Rev. Growth||317000 %|
|Gross Profit (p.s.)||-54.64|
|Sales Per Share||-106.91|
|Qtrly Earnings Growth||-0.4 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||-162 (M)|
|Price to Book value||0|
|Price to Sales||-0.02|
|Price to Cash Flow||3.17|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|